<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102413</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-CKD-02</org_study_id>
    <nct_id>NCT01102413</nct_id>
  </id_info>
  <brief_title>Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia</brief_title>
  <official_title>A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>India: Central Drugs Standard Control Organization</authority>
    <authority>India: Institutional Review Board</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>US: FOOD AND DRUG ADMINISTRATION (FDA) and WESTERN INSTITUTIONAL REVIEW BOARD (WIRB)</authority>
    <authority>Poland:Department for Clinical Trials of Medicinal Products Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and Ethics Committee at the Regional Medical Chamber in Warsaw</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Romania: National Agency for Drug and Medical Devices and National Ethics Committee for Drug Clinical Trial</authority>
    <authority>Austria: BASG/AGES and Ethikkommission des Landes Oberösterreich</authority>
    <authority>Germany: Ethikkommission der Ärztekammer Niedersachsen and BfArM</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to determine the effects of an investigational drug Monofer in
      subjects with non-dialysis dependent chronic kidney disease (NDD-CKD) subjects and with iron
      deficiency anaemia (IDA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Concentration From Baseline to Week 8</measure>
    <time_frame>Baseline to week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Monofer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injections or infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron Sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monofer</intervention_name>
    <description>Infusion or injections</description>
    <arm_group_label>Monofer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sulphate</intervention_name>
    <description>Oral intake</description>
    <arm_group_label>Iron Sulphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged more than 18 years.

          2. Subjects diagnosed with NDD-CKD with MDRD calculated eGFR between 15-59 mL/min.

          3. Hb &lt; 11.0 g/dL (6.80 mmol/L)

          4. Either or both of the following iron stores indicators below target {Serum ferritin &lt;
             100 ug/l and Transferrin saturation (TfS)&lt;20%}.

          5. Life expectancy beyond 12 months by Principal Investigator's judgement.

          6. Willingness to participate after informed consent and any authorization as required
             by local law ( e.g. Protected Health Information [PHI] for North America).

        Exclusion Criteria:

          1. Anaemia predominantly caused by factors other than renal impairment or iron
             deficiency (according to Principal Investigator's judgment).

          2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and
             haemosiderosis).

          3. Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono-
             or disaccharide complexes or to iron sulphate or any excipients of the study drug.

          4. Subjects with history of multiple allergies.

          5. Decompensated liver cirrhosis or active hepatitis (Alanine Aminotransferase (ALT) &gt; 3
             times upper normal limit).

          6. Active acute or chronic infections ((assessed by clinical judgment), supplied with
             White Blood Cells (WBC) and C-Reactive Protein (CRP)).

          7. Rheumatoid arthritis with symptoms or signs of active joint inflammation.

          8. Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least
             12 months must have elapsed since last menstruation), surgically sterile, or women of
             child bearing potential must use one of the following contraceptives during the whole
             study period and after the study has ended for at least 5 times plasma biological
             half-life of the investigational medicinal product (5 days): Contraceptive pills,
             intrauterine devices (IUD), contraceptive depot injections (prolonged-release
             gestagen), subdermal implantation, vaginal ring, and transdermal patches).

          9. Extensive active bleeding necessitating blood transfusion.

         10. Planned elective surgery during the study.

         11. Participation in any other clinical study within 3 months prior to screening.

         12. Known intolerance to oral iron treatment.

         13. Untreated B12 or folate deficiency.

         14. I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening
             visit.

         15. ESA treatment within 8 weeks prior to screening visit.

         16. Serum ferritin &gt; 500 µg/L.

         17. Any other medical condition that, in the opinion of Principal Investigator, may cause
             the subject to be unsuitable for the completion of the study or place the subject at
             potential risk from being in the study or interfere with study drug evaluation.
             Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled
             Diabetes Mellitus.

         18. Body weight &lt; 30 kilograms.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmacosmos</name>
      <address>
        <city>Holbaek</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 2, 2015</lastchanged_date>
  <firstreceived_date>March 26, 2010</firstreceived_date>
  <firstreceived_results_date>September 21, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Monofer</title>
          <description>Injections or infusions
Monofer: Infusion or injections</description>
        </group>
        <group group_id="P2">
          <title>Iron Sulphate</title>
          <description>Oral intake
Iron Sulphate: Oral intake</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Monofer</title>
          <description>Injections or infusions
Monofer: Infusion or injections</description>
        </group>
        <group group_id="B2">
          <title>Iron Sulphate</title>
          <description>Oral intake
Iron Sulphate: Oral intake</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="233"/>
                <measurement group_id="B2" value="118"/>
                <measurement group_id="B3" value="351"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="164"/>
                <measurement group_id="B2" value="80"/>
                <measurement group_id="B3" value="244"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="107"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="141"/>
                <measurement group_id="B2" value="54"/>
                <measurement group_id="B3" value="195"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="92"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="156"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Denmark</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Austria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>India</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="138"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="202"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Sweden</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.</title>
        <time_frame>Baseline, 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The FAS population included all the subjects who were randomised into the study, received at least one dose of the study drug, and had at least one post-baseline Hb assessment. The subjects were considered as randomised, regardless of which treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Monofer</title>
            <description>Injections or infusions
Monofer: Infusion or injections</description>
          </group>
          <group group_id="O2">
            <title>Iron Sulphate</title>
            <description>Oral intake
Iron Sulphate: Oral intake</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="209"/>
                  <measurement group_id="O2" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.</title>
            <units>g/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.57" lower_limit="-3.1" upper_limit="4.0"/>
                  <measurement group_id="O2" value="0.35" lower_limit="-3.7" upper_limit="3.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Concentration From Baseline to Week 8</title>
        <time_frame>Baseline to week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>The FAS population included all the subjects who were randomised into the study, received at least one dose of the study drug, and had at least one post-baseline Hb assessment. The subjects were considered as randomised, regardless of which treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Monofer</title>
            <description>Injections or infusions
Monofer: Infusion or injections</description>
          </group>
          <group group_id="O2">
            <title>Iron Sulphate</title>
            <description>Oral intake
Iron Sulphate: Oral intake</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="210"/>
                  <measurement group_id="O2" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Hemoglobin Concentration From Baseline to Week 8</title>
            <units>g/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.92" lower_limit="-1.6" upper_limit="5.1"/>
                  <measurement group_id="O2" value="0.45" lower_limit="-2.9" upper_limit="4.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population included all subjects who were randomised and received at least one dose of iron isomaltoside 1000 or iron sulphate. The safety analyses was performed on the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Monofer</title>
          <description>Injections or infusions
Monofer: Infusion or injections</description>
        </group>
        <group group_id="E2">
          <title>Iron Sulphate</title>
          <description>Oral intake
Iron Sulphate: Oral intake</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary track infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Odema peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If Pharmacosmos or its agents has not prepared a draft for submission to a peer reviewed journal prior to 1 year following completion of the study report, the investigators have the right to publish the results. Such publications are to be submitted to Pharmacosmos for comment 30 days prior to submision for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Research &amp; Development Department</name_or_title>
      <organization>Pharmacosmos A/S</organization>
      <phone>+45 59485959</phone>
      <email>llt@pharmacosmos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
